Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. Show more

Location: Dr. Neergaards Vej, Horsholm, 2970, Denmark | Website: https://evaxion.ai | Industry: Biotechnology | Sector: Healthcare


Market Cap

45.56M

52 Wk Range

$1.20 - $14.38

Previous Close

$5.75

Open

$5.73

Volume

100,969

Day Range

$5.60 - $5.93

Enterprise Value

26.48M

Cash

14.75M

Avg Qtr Burn

-2.92M

Insider Ownership

18.39%

Institutional Own.

5.44%

Qtr Updated

06/30/25